Skip to main content
SpringerLink
Log in

Comparative activities of sitafloxacin against recent clinical isolates in hospitals across China

  • Original Article
  • Published:
European Journal of Clinical Microbiology & Infectious Diseases Aims and scope Submit manuscript

Abstract

Sitafloxacin is one of the newer generation fluoroquinolones. Considering the ever-changing antimicrobial resistance, it is necessary to monitor the activities of sitafloxacin against recent pathogenic isolates. Therefore, we determined the minimum inhibitory concentrations (MICs) of sitafloxacin and comparators by broth microdilution or agar dilution method against 1101 clinical isolates collected from 2017 to 2019 in 31 hospitals across China. Sitafloxacin was highly active against gram-positive isolates evidenced by the MICs required to inhibit the growth of 50%/90% isolates (MIC50/90): ≤ 0.03/0.25, ≤ 0.03/0.125, ≤ 0.03/2, 0.125/0.25, 0.25/2, and 0.125/0.125 mg/L for methicillin-susceptible Staphylococcus aureus (MSSA), methicillin-susceptible coagulase-negative Staphylococcus (MSCNS), methicillin-resistant S. aureus (MRSA), methicillin-resistant CNS, Enterococcus faecalis, and Streptococcus pneumoniae, respectively. Sitafloxacin inhibited 82.8% of the MRSA strains and 97.5% of MRCNS strains. Sitafloxacin was also potent against ciprofloxacin-susceptible Escherichia coli (MIC50/90: ≤ 0.03/0.06 mg/L) and Klebsiella pneumoniae (MIC50/90: ≤ 0.03/0.125 mg/L), non-ESBL-producing E. coli (MIC50/90: ≤ 0.03/1 mg/L) and K. pneumoniae (MIC50/90: ≤ 0.03/0.5 mg/L), Haemophilus influenzae (MIC50/90: ≤0.015/0.06 mg/L), Haemophilus parainfluenzae (MIC50/90: 0.125/0.5 mg/L), Moraxella catarrhalis (MIC50/90: ≤ 0.015/≤ 0.015 mg/L), Bacteroides fragilis (MIC50/90: 0.06/2 mg/L), Peptostreptococcus (MIC50/90: 0.125/4 mg/L), and Mycoplasma pneumoniae (≤ 0.03/≤ 0.03 mg/L). However, sitafloxacin was less active for Enterococcus faecium, ciprofloxacin-resistant and/or ESBL-producing E. coli, and K. pneumoniae strains. Sitafloxacin was superior or comparable to most of the comparators in activities against the abovementioned isolates, so sitafloxacin is still highly active against most of the clinical isolates in hospitals across China, proving its utility in treatment of the abovementioned susceptible strains.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

Data availability

Data can be provided upon request.

References

  1. Asakura T, Suzuki S, Fukano H et al (2019) Sitafloxacin-containing regimen for the treatment of refractory Mycobacterium avium complex lung disease. Open Forum Infect Dis 6:ofz108

    Article  Google Scholar 

  2. Manosuthi W, Wiboonchutikul S (2016) Treatment outcomes of oral sitafloxacin in acute complicated urinary tract infection and pyelonephritis. Springerplus 5:410

    Article  Google Scholar 

  3. Keating GM (2011) Sitafloxacin: in bacterial infections. Drugs 71:731–744

    Article  CAS  Google Scholar 

  4. Hamasuna R, Ohnishi M, Matsumoto M et al (2018) In Vitro activity of sitafloxacin and additional newer generation fluoroquinolones against ciprofloxacin-resistant Neisseria gonorrhoeae isolates. Microb Drug Resist 24:30–34

    Article  CAS  Google Scholar 

  5. Tantisiriwat W, Linasmita P (2017) In vitro activity of sitafloxacin and other antibiotics against bacterial isolates from HRH Princess Maha Chakri Sirindhorn Medical Center, Srinakharinwirot University and Samitivej Sukhumvit Hospital. J Med Assoc Thail 100:469–478

    Google Scholar 

  6. Xu N, Wang G, Leng Y et al (2018) Sulbactam enhances the in vitro activity of sitafloxacin against extensively-drug resistant Acinetobacter baumannii. ExpTher Med 16:3485–3491

    Google Scholar 

  7. Clinical and Laboratory Standards Institute (2020) Performance standards for antimicrobial susceptibility testing; M100 30th. Clin Lab Stand Instit

  8. CLSI (2018) M07, 11th Ed. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. Clinical and Laboratory Standards Institute, Wayne

    Google Scholar 

  9. CLSI (2011) Methods for antimicrobial susceptibility testing for human mycoplasmas; approved guideline (M43-A). Clinical and Laboratory Standards Institute, Wayne

    Google Scholar 

  10. Hu F, Guo Y, Yang Y et al (2019) Resistance reported from China antimicrobial surveillance network (CHINET) in 2018. Eur J Clin Microbiol Infect Dis 38:2275–2281

    Article  CAS  Google Scholar 

  11. Milatovic D, Schmitz FJ, Brisse S, Verhoef J, Fluit AC (2000) In vitro activities of sitafloxacin (DU-6859a) and six other fluoroquinolones against 8,796 clinical bacterial isolates. Antimicrob Agents Chemother 44:1102–1107

    Article  CAS  Google Scholar 

  12. Schmitz FJ, Fluit AC, Milatovic D et al (2000) In vitro potency of moxifloxacin, clinafloxacin and sitafloxacin against 248 genetically defined clinical isolates of Staphylococcus aureus. J Antimicrob Chemother 46:109–113

    Article  CAS  Google Scholar 

  13. Amano A, Matsuzaki K, Kishi N et al (2013) In vitro activity of sitafloxacin against clinical isolates in 2012. Jpn J Antibiot 66:311–330 [Japanese]

    Article  CAS  Google Scholar 

  14. Doern GV, Heilmann KP, Huynh HK et al (2001) Antimicrobial resistance among clinical isolates of Streptococcus pneumoniae in the United States during 1999-2000, including a comparison of resistance rates since 1994-1995. Antimicrob Agents Chemother 45:1721–1729

    Article  CAS  Google Scholar 

  15. Snydman DR, Jacobus NV, McDermott LA et al (2002) In vitro activities of newer quinolones against Bacteroides group organisms [Errata in Antimicrob Agents Chemother 2003;47(2):831]. Antimicrob Agents Chemother 46:3276–3279

    Article  CAS  Google Scholar 

  16. Tanigawara Y, Kaku M, Totsuka K, Tsuge H, Saito A (2013) Population pharmacokinetics and pharmacodynamics of sitafloxacin in patients with community-acquired respiratory tract infections. J Infect Chemother 19:858–866

    Article  CAS  Google Scholar 

Download references

Code availability

Not applicable.

Funding

This work was supported by National Mega-project for Innovative Drugs (2019ZX09721001-006-004), and CHINET Antimicrobial Surveillance Network (grant number WI207259).

Author information

Authors and Affiliations

  1. Institute of Antibiotics, Huashan Hospital, Fudan University, 12 M. Wulumuqi Rd., Shanghai, 200040, China

    Shi Wu, Yang Yang, Yan Guo, Dandan Yin, Yonggui Zheng, Renru Han, Li Ding, Demei Zhu & Fupin Hu

  2. Key Laboratory of Clinical Pharmacology of Antibiotics, Ministry of Health, Shanghai, China

    Shi Wu, Yang Yang, Yan Guo, Dandan Yin, Yonggui Zheng, Renru Han, Li Ding, Demei Zhu & Fupin Hu

Authors
  1. Shi Wu
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Yang Yang
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Yan Guo
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Dandan Yin
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Yonggui Zheng
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Renru Han
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Li Ding
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Demei Zhu
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Fupin Hu
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Fupin Hu.

Ethics declarations

Ethics approval

This study was approved by the Institutional Review Board of Huashan Hospital, Fudan University (number: 2019-572).

Consent to participate

Not applicable.

Consent for publication

Not applicable.

Conflict of interest

The authors declare no competing interests.

Additional information

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Wu, S., Yang, Y., Guo, Y. et al. Comparative activities of sitafloxacin against recent clinical isolates in hospitals across China. Eur J Clin Microbiol Infect Dis 40, 2271–2283 (2021). https://doi.org/10.1007/s10096-021-04278-3

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10096-021-04278-3

Keywords

Search

Navigation